Seer Inc. Q2 2026 Earnings: Revenue Misses $3.1 Million

Seer Inc. (Nasdaq: SEER) reported Q2 2026 revenue of $3.1 million, below consensus of $4.0 million, and a net loss of $0.31 per share versus a $0.22 loss expected. The company reaffirmed full-year 2026 revenue guidance of $16 million to $18 million. Shares fell about 2.78% after hours to $2.10.

Original reporting
Published Aug 14, 2026, 11:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 12:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Seer Inc. Q2 2026 Earnings: Revenue Misses $3.1 Million — source image
Decision brief

The 30-second read

$SEERBearishMed
01

Why it matters

The key tradable signal is the Q2 revenue miss versus consensus and the immediate after-hours decline, partially offset by lower operating expenses and reaffirmed FY revenue guidance.

02

Market read

Traders likely reprice near-term growth expectations after the Q2 revenue shortfall, while monitoring whether cost cuts translate into accelerating revenue in subsequent quarters.

03

What to watch

Large cash balance ($209.5M) and gross margin near 49% could reduce balance-sheet risk, potentially cushioning further downside if revenue stabilizes.

Relevance 8/10Novelty 8/10Timing: after-hours reaction on 2026-08-14 earnings release

Background

Seer is a proteomics technology company selling research-use-only Proteograph instruments, consumables, and software.

Company-level read

Ticker impact

$SEERBearishMedium confidence
Context

Seer reported Q2 2026 revenue of $3.1M, below $4.0M consensus, and shares fell 2.78% after hours despite reaffirmed full-year guidance.

Expected impact

Bearish bias for the next few sessions as investors weigh the revenue shortfall versus guidance reaffirmation.

Evidence & confidence

The article provides a concrete earnings miss (revenue and EPS vs consensus) plus the immediate after-hours reaction, while noting operating expense reductions and unchanged FY revenue range.

Market effects

Reinforces that early-stage proteomics tools companies can see valuation pressure when revenue growth lags, even with cost discipline.

Limited, company-specific move for a small-cap Nasdaq name.

Low, no cross-border deal, regulation, or supply-chain shock described.

Counterpoint

Cost reductions and reaffirmed FY guidance may indicate the miss is temporary, with operating leverage improving into later quarters.

Key entities

  • Seer Inc.

    Proteomics technology company reporting Q2 2026 results and reaffirming FY 2026 revenue guidance.

  • Omid Farokhzad

    CEO who highlighted customer presentations on AI-driven proteomics at ASMS.

  • David Horn

    CFO who reaffirmed FY 2026 revenue guidance of $16M to $18M.

Related articles

$SEERMed

Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance

Seer, Inc. (SEER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Seer Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Revenue Guidance REDWOOD CITY, Calif. – November 10, 2026 – Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced fin

$SEERMed

Seer wins ITC staff backing for import ban on Nanomics products

Seer, Inc. (SEER) announced that the U.S. International Trade Commission's staff recommended an import ban on Nanomics' products, alleging patent infringement. The ITC is expected to make a final decision by year-end. Seer also reported recent patent victories in the U.S. and Europe. The company develops proteomics technology and is involved in a related lawsuit against Nanomics.